Skip to content

⌘K

Screener Chart SD50 Calendar News DevelopersAPI

Home Chart Screener Calendar News

Metro Inc. (MTRI) Stock | LOPJLB

Mentari Therapeutics, Inc. (MTRI)

Healthcare · Biotechnology · NASDAQ · US

$18.60+1.36%Close

The free White Arrow call is the 25-name SPY25 preview. Essential unlocks MTRI.

MTRI

$18.60+1.36%

Overview Financials Earnings Analyst & RatingsAnalyst News Holders & ETFsHolders Options

Snapshot

Price & returns

1 week: +19.5%+16.9% vs SPY
1 month: +39.8%+42.9% vs SPY

Valuation

Market cap: $6.8B
P/E: negindustry 14.9
P/B: -8.5
EV/EBITDA: 116.4
FCF yield: -88.4%

Street & earnings

Consensus: Buy2 buy · 0 hold · 0 sell
Price target: $30.00+61.3% upside

Signal evidence

Prediction markets

… linked markets on Kalshi and Polymarket.

Full prediction markets →

Loading markets…

Company

Healthcare · Biotechnology · CEO Gregory J. Divis

About

Mentari Therapeutics, Inc. (MTRI). Mentari Therapeutics, Inc. is a biotechnology company, which engages in developing therapies for migraine prevention. Its portfolio includes MT-001 and MT-002. The company was founded on June 13, 2025 and is headquartered in Waltham, MA.

SEC filingsCIK 1728328

All filings
10-K
10-Q
8-K
Form 4

Profile

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

CountryUS

CEOGregory J. Divis

IPOMay 5, 2014

Employees6

Shares outstanding368.3M

Float0

Free float0.0%

Websitementaritx.com ↗

Key executives

Thomas W. WelchChairman & Chief Executive Officer
Michael D. WelchPres and Director
Alex SolomonovicChief Scientific Officer and Vice President

Snapshot

Price & returns1 month +39.8%

1 week: +19.5%+16.9% vs SPY
1 month: +39.8%+42.9% vs SPY

Open the chart →

ValuationP/E neg vs industry 14.9 · market cap $6.8B

Market cap: $6.8B
P/E: negindustry 14.9
P/B: -8.5
EV/EBITDA: 116.4
FCF yield: -88.4%

Open Financials →

Street & earningsTarget $30.00 (+61.3% upside)2 buy · 0 hold · 0 sell

Consensus: Buy2 buy · 0 hold · 0 sell
Price target: $30.00+61.3% upside

Open Analyst →

Signal evidence

Prediction markets

… linked markets on Kalshi and Polymarket.

Full prediction markets →

Loading markets…

Company

Healthcare · Biotechnology · CEO Gregory J. Divis

About

Mentari Therapeutics, Inc. (MTRI). Mentari Therapeutics, Inc. is a biotechnology company, which engages in developing therapies for migraine prevention. Its portfolio includes MT-001 and MT-002. The company was founded on June 13, 2025 and is headquartered in Waltham, MA.

SEC filingsCIK 1728328

All filings
10-K
10-Q
8-K
Form 4

Profile

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

CountryUS

CEOGregory J. Divis

IPOMay 5, 2014

Employees6

Shares outstanding368.3M

Float0

Free float0.0%

Websitementaritx.com ↗

Key executives

Thomas W. WelchChairman & Chief Executive Officer
Michael D. WelchPres and Director
Alex SolomonovicChief Scientific Officer and Vice President

Company news

globenewswire.com · 5d ago

Mentari Therapeutics to Present at Upcoming Investor Conferences

prnewswire.com · 8d ago

InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

newsfilecorp.com · 9d ago

InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"

newsfilecorp.com · 10d ago

InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation

newsfilecorp.com · 12d ago

InMed Announces Share Consolidation in Connection with Proposed Merger

newsfilecorp.com · 19d ago

InMed Announces CVR Distribution Record Date in Connection with Proposed Merger

newsfilecorp.com · 57d ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

Market news & ticker search · RSS for MTRI

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Market Regime Track Record Docs Editorial Blog Changelog

Ledgers

Bull Spreads Bear Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener Best dividend stocks Undervalued stocks Best S&P 500 stocks

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCP(every plan)·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

OHLCOHLC, Essential layerEMAEMALevels, Essential layerStopStop, Essential layerFlipFlip, Essential layer52-week52-weekSignals, Essential layerBuyBuy, Essential layerSellSell, Essential layerExhaustionExhaustion, Essential layerExhaustion zoneExhaustion zone, Essential layerCoilCoil, Essential layerBest ComboBest Combo

LOPJLB.COM

Nov 13, 2026O 19.02H 20.00L 18.40C 18.60+1.36%V 11.9K